Trial Profile
Protective Effect of Rosuvastatin and Antiplatelet Therapy On Contrast-induced Nephropathy and Myocardial Damage in Patients With Acute Coronary Syndrome Undergoing Coronary Intervention; PRATO-ACS Trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Rosuvastatin (Primary) ; Atorvastatin
- Indications Acute kidney injury
- Focus Therapeutic Use
- Acronyms PRATO-ACS
- 15 Nov 2017 Results assessing the efficacy of high-dose atorvastatin and rosuvastatin in preventing renal damage presented at the 90th Annual Scientific Sessions of the American Heart Association
- 28 Mar 2014 New trial record